(secondQuint)ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past.

 All patients take ABT-378/ritonavir and efavirenz; there are no placebos in this study.

 Patients take study medications for 48 weeks, during which time there will be 15 study visits.

 There is a possibility of a study extension after 48 weeks.

.

 ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past@highlight

The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).

